These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33199881)

  • 41. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
    Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Factors Associated with the Antihypertensive Effect of Esaxerenone and Serum Potassium Elevation: A Pooled Analysis of Seven Phase III Studies.
    Ito S; Okuda Y; Sugimoto K
    Adv Ther; 2023 Mar; 40(3):1242-1266. PubMed ID: 36662393
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey.
    Mori Y; Nishikawa Y; Iizuka T; Zenimura N; Matsumoto T; Hiramatsu K; Komiya M
    Drugs R D; 2011; 11(2):171-90. PubMed ID: 21679007
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Absolute Bioavailability of Esaxerenone and Food Effects on its Pharmacokinetics After a Single Oral Dose in Healthy Japanese Subjects: An Open-Label Crossover Study.
    Kurata A; Furuie H; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
    Adv Ther; 2019 Jul; 36(7):1618-1627. PubMed ID: 31119692
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rationale and Design of the Efficacy and Safety of Esaxerenone in Hypertensive Patients With Left Ventricular Hypertrophy (ESES-LVH) Study　- Protocol for a Multicenter, Open-Label, Exploratory Interventional Study.
    Sueta D; Yamamoto E; Usuku H; Suzuki S; Nakamura T; Matsui K; Akasaka T; Shiosakai K; Sugimoto K; Tsujita K;
    Circ Rep; 2022 Feb; 4(2):99-104. PubMed ID: 35178486
    [No Abstract]   [Full Text] [Related]  

  • 46. Effects of itraconazole and rifampicin on the single-dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects.
    Kirigaya Y; Shiramoto M; Ishizuka T; Uchimaru H; Irie S; Kato M; Shimizu T; Nakatsu T; Nishikawa Y; Ishizuka H
    Br J Clin Pharmacol; 2020 Oct; 86(10):2070-2079. PubMed ID: 32250463
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
    Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
    Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone.
    Ori Y; Chagnac A; Korzets A; Zingerman B; Herman-Edelstein M; Bergman M; Gafter U; Salman H
    Nephrol Dial Transplant; 2013 Jul; 28(7):1787-93. PubMed ID: 23378418
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.
    Seifarth C; Trenkel S; Schobel H; Hahn EG; Hensen J
    Clin Endocrinol (Oxf); 2002 Oct; 57(4):457-65. PubMed ID: 12354127
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of two fixed-dose combinations of S-amlodipine and telmisartan (CKD-828) versus S-amlodipine monotherapy in patients with hypertension inadequately controlled using S-amlodipine monotherapy: an 8-week, multicenter, randomized, double-blind, Phase III clinical study.
    Ihm SH; Jeon HK; Cha TJ; Hong TJ; Kim SH; Lee NH; Yoon JH; Yoon N; Hwang KK; Jo SH; Youn HJ
    Drug Des Devel Ther; 2016; 10():3817-3826. PubMed ID: 27920497
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
    Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
    Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses.
    Fernet M; Beckerman B; Abreu P; Lins K; Vincent J; Burgess E
    Vasc Health Risk Manag; 2018; 14():233-246. PubMed ID: 30275698
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of mineralocorticoid receptor antagonists on sex hormones and body composition in patients with primary aldosteronism.
    Ishikawa T; Morimoto S; Ichihara A
    Hypertens Res; 2022 Mar; 45(3):496-506. PubMed ID: 34961793
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis.
    Malacco E; Omboni S; Mallion JM; Volpe M;
    High Blood Press Cardiovasc Prev; 2012 Dec; 19(4):213-22. PubMed ID: 23430666
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of esaxerenone in patients with hypertension and concomitant heart failure.
    Naruke T; Maemura K; Oki T; Yazaki M; Fujita T; Ikeda Y; Nabeta T; Ishii S; Minami Y; Fukaya H; Yuge M; Shimohama T; Kawaguchi T; Ako J
    Hypertens Res; 2021 May; 44(5):601-603. PubMed ID: 33420475
    [No Abstract]   [Full Text] [Related]  

  • 57. Antihypertensive Effects of Esaxerenone in Older Patients with Primary Aldosteronism.
    Fujimoto M; Watanabe S; Igarashi K; Ruike Y; Ishiwata K; Naito K; Ishida A; Koshizaka M; Suzuki S; Shiko Y; Koide H; Yokote K
    Int J Hypertens; 2023; 2023():6453933. PubMed ID: 36704237
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.
    Morimoto S; Ichihara A
    Hypertens Res; 2020 Aug; 43(8):744-753. PubMed ID: 32424201
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study.
    Lim PO; Jung RT; MacDonald TM
    Br J Clin Pharmacol; 1999 Nov; 48(5):756-60. PubMed ID: 10594479
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Switching patients with uncontrolled hypertension on amlodipine 10 mg to single-pill combinations of telmisartan and amlodipine: results of the TEAMSTA-10 study.
    Neldam S; Edwards C; Jones R;
    Curr Med Res Opin; 2011 Nov; 27(11):2145-53. PubMed ID: 21955225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.